Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine.

• 5 March 2002
• journal article
• clinical trial
• Published by Elsevier in Journal of Psychiatric Research
• Vol. 36  (3) , 111-118
• https://doi.org/10.1016/s0022-3956(01)00055-3

Abstract

Keywords

• VENLAFAXINE XR
• FLUOXETINE
• GLOBAL BENEFIT-RISK
• REMISSION
• RESPONSE